Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib dose-escalation of BI 907828 + ezabenlimab (BI 754091) ± BI 754111 in advanced solid tumors
jRCT2080224759Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of brigimadlin, ezabenlimab and miptenalimab in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Started Jul 2019; status: completed.
02
Drugs
brigimadlinezabenlimabmiptenalimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224759.